Isofluran Baxter (Isoflurane)

Isoflurane works by enhancing the activity of the GABA_A receptor, which increases inhibitory chloride currents in the central nervous system, and by blocking NMDA receptors, reducing excitatory glutamate signaling. The combined effect depresses neuronal activity, leading to unconsciousness and loss of pain perception.

The specific dose of Isofluran Baxter is determined by the treating anesthesiologist based on the patient’s age, weight, medical condition, and the type of surgery. Dosage is titrated to achieve the desired depth of anesthesia and is adjusted throughout the procedure.

Safety data for Isofluran Baxter in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To order Isofluran Baxter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Isoflurane is comparable to other volatile anesthetics such as sevoflurane and desflurane. Compared with sevoflurane, Isoflurane is less expensive but may cause more airway irritation and a slightly slower emergence. All agents share similar mechanisms of GABA_A potentiation and NMDA inhibition, with differences in pharmacokinetics and side‑effect profiles.

Isofluran Baxter should be stored at room temperature, away from direct sunlight and moisture. Keep the container tightly sealed when not in use, and handle it in a well‑ventilated area to avoid inhalation of vapors. Follow all local regulations for hazardous chemicals.

Isofluran Baxter is supplied as a liquid solution for inhalation. It is vaporized by an anesthesia machine and delivered to the patient through a breathing circuit, allowing precise control of the inspired concentration to achieve the desired anesthetic depth.

The most serious risks include malignant hyperthermia, a rare but life‑threatening hypermetabolic reaction, severe cardiac arrhythmias, and significant hepatotoxicity. Prompt recognition and treatment of these events are essential to prevent morbidity and mortality.

Isofluran Baxter should be avoided in patients with a known hypersensitivity to volatile anesthetics, a personal or family history of malignant hyperthermia, severe uncontrolled cardiovascular disease, or in situations where alternative anesthesia techniques are safer. Clinical judgment is required for each individual case.